Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nabi Seeking StaphVAX Indication For All At-Risk Groups; BLA By End Of 2005

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Nabi is initiating immunogenicity trials of its S. aureus vaccine StaphVAX in new patient groups in hopes of securing a broad approval for use in all at-risk adults.

You may also be interested in...



Nabi Discontinues StaphVax After Confirmatory Phase III Trial Fails

Nabi Biopharmaceuticals is halting development of its Staphylococcus aureus vaccine StaphVax after the product's failure to show efficacy in a 3,600-patient confirmatory trial

Nabi revises StaphVax study

Nabi will increase the number of end-stage renal disease patients in a confirmatory Phase III trial of its Staphylococcus aureus vaccine, StaphVax, from 3,000 to 3,600. "The decision to expand the sample size was made following additional dialogue with FDA as to what would constitute a meaningful effect in the context of the adverse event profile," the company says. The larger patient population will power the study to show statistical significance with a clinical reduction of 50% or more in S. aureus infections through eight months post-vaccination; the initial Phase III study showed significant results through 10 months at a 60% reduction rate. The company estimates approximately 12 mil. U.S. patients are at risk of contracting an S. aureus infection. Nabi plans to submit an NDA by the end of 2005...

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

Topics

UsernamePublicRestriction

Register

PS002602

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel